萘福昔定与炔雌醇治疗晚期乳腺癌的对比试验：一项欧洲癌症研究与治疗组织（E.O.R.T.C.）的研究
Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study.
作者信息
Heuson J C, Engelsman E, Blonk-Van Der Wijst J, Maass H, Drochmans A, Michel J, Nowakowski H, Gorins A
出版信息
Br Med J. 1975 Jun 28;2(5973):711-3. doi: 10.1136/bmj.2.5973.711.
Abstract
A randomized clinical trial of nafoxidine, a non-steroidal oestrogen antagonist, and ethinyloestradiol in postmenopausal patients with advanced breast cancer produced objective remissions in 31% of 49 women receiving nafoxidine and in 14% of 49 receiving ethinyloestradiol. The differences in remission rates was almost significant (0.05 less than P less than 0.10). Life-threatening complications were more frequent with ethinyloestradiol than with nafoxidine but the latter produced specific toxic reactions on skin and hair that may limit its practical usefulness. Synthetic oestrogen antagonists may occupy a privileged place in the treatment of breast cancer, and other representatives of this new class of compounds should be accurately assessed in randomized clinical trials.
摘要
一项关于非甾体雌激素拮抗剂萘福昔定与炔雌醇在绝经后晚期乳腺癌患者中的随机临床试验显示，49名接受萘福昔定治疗的女性中有31%出现客观缓解，49名接受炔雌醇治疗的女性中有14%出现客观缓解。缓解率的差异几乎具有显著性（0.05＜P＜0.10）。与萘福昔定相比，炔雌醇导致的危及生命的并发症更为常见，但后者会对皮肤和头发产生特定的毒性反应，这可能会限制其实际应用。合成雌激素拮抗剂在乳腺癌治疗中可能占据特殊地位，这类新型化合物的其他代表物应在随机临床试验中进行准确评估。
相似文献
1
Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study.萘福昔定与炔雌醇治疗晚期乳腺癌的对比试验：一项欧洲癌症研究与治疗组织（E.O.R.T.C.）的研究
Br Med J. 1975 Jun 28;2(5973):711-3. doi: 10.1136/bmj.2.5973.711.
2
Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an E.O.R.T.C. study.左旋多巴与萘福昔定治疗晚期乳腺癌的对照临床试验：一项欧洲癌症研究与治疗组织（E.O.R.T.C.）的研究
Br Med J. 1975 Jun 28;2(5973):714-5. doi: 10.1136/bmj.2.5973.714.
3
Antiestrogens in treatment of breast cancer.抗雌激素药物在乳腺癌治疗中的应用
Cancer. 1977 Jun;39(6 Suppl):2959-64. doi: 10.1002/1097-0142(197706)39:6<2959::aid-cncr2820390682>3.0.co;2-2.
4
Antioestrogens in treatment of breast cancer: value of nafoxidine in 52 advanced cases.抗雌激素药物治疗乳腺癌：52例晚期病例中萘福昔定的价值。
Br Med J. 1974 Apr 6;2(5909):7-10. doi: 10.1136/bmj.2.5909.7.
5
[Prolactin: radioimmunologic levels and changes under ethinyl estradiol and nafoxidine in advanced breast cancers in women].[催乳素：女性晚期乳腺癌患者在乙炔雌二醇和萘福昔定作用下的放射免疫水平及变化]
Ann Endocrinol (Paris). 1973 Sep-Oct;34(5):601-2.
6
Clinical trial of nafoxidine in advanced breast cancer.奈福西定治疗晚期乳腺癌的临床试验。
Med Pediatr Oncol. 1978;4(2):123-6. doi: 10.1002/mpo.2950040207.
7
Clinical trial of nafoxidine in adrenalectomized patients with advanced breast cancer.萘福昔定用于肾上腺切除术后晚期乳腺癌患者的临床试验。
Cancer. 1977 Nov;40(5):2063-6. doi: 10.1002/1097-0142(197711)40:5<2063::aid-cncr2820400511>3.0.co;2-w.
8
Therapy with nafoxidine for patients suffering from postmenopausal ulcerated mammary cancer.诺氟沙星对绝经后溃疡性乳腺癌患者的治疗。
Panminerva Med. 1976 Mar-Apr;18(3-4):137-41.
9
Nafoxidine--an antiestrogen for the treatment of breast cancer.萘福昔定——一种用于治疗乳腺癌的抗雌激素药物。
Cancer. 1976 Oct;38(4):1535-41. doi: 10.1002/1097-0142(197610)38:4<1535::aid-cncr2820380415>3.0.co;2-m.
10
[Treatment of breast cancers with antiestrogens. Clinical study of nafoxidine].[用抗雌激素治疗乳腺癌。萘福昔定的临床研究]
Nouv Presse Med. 1977 Dec 24;6(44):4145-6.
引用本文的文献
1
Efficacy and tolerability of high dose "ethinylestradiol" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents.高剂量“炔雌醇”在接受过大量内分泌药物预处理的绝经后晚期乳腺癌患者中的疗效和耐受性。
World J Surg Oncol. 2006 Jul 11;4:44. doi: 10.1186/1477-7819-4-44.
2
Preventive effects of antioestrogen on mammary and pituitary tumorigenesis in rats.抗雌激素对大鼠乳腺和垂体肿瘤发生的预防作用。
Br J Cancer. 1984 Dec;50(6):779-84. doi: 10.1038/bjc.1984.256.
3
Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance.他莫昔芬在动物和人体内的代谢产物：鉴定、药理学及意义
Breast Cancer Res Treat. 1982;2(2):123-38. doi: 10.1007/BF01806449.
4
Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites.抗雌激素在乳腺癌细胞中的作用：对增殖和蛋白质合成的调节，以及与雌激素受体和其他抗雌激素结合位点的相互作用。
Breast Cancer Res Treat. 1985;5(3):231-43. doi: 10.1007/BF01806018.
5
Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an E.O.R.T.C. study.左旋多巴与萘福昔定治疗晚期乳腺癌的对照临床试验：一项欧洲癌症研究与治疗组织（E.O.R.T.C.）的研究
Br Med J. 1975 Jun 28;2(5973):714-5. doi: 10.1136/bmj.2.5973.714.
本文引用的文献
1
Anti-oestrogens and breast cancer.抗雌激素与乳腺癌
Eur J Cancer (1965). 1971 Feb;7(1):57-64. doi: 10.1016/0014-2964(71)90095-8.
2
Inhibition of DMBA-induced mammary carcinogenesis in the rat by 2-br- -ergocryptine (CB 154), an inhibitor of prolactin secretion, and by nafoxidine (U-11, 100 A), an estrogen antagonist.催乳素分泌抑制剂2-溴-α-麦角隐亭（CB 154）和雌激素拮抗剂那法瑞林（U-11,100 A）对二甲基苯并蒽（DMBA）诱导的大鼠乳腺癌发生的抑制作用。
Gynecol Invest. 1971;2(1):130-7. doi: 10.1159/000301858.
3
A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474.一种用于晚期乳腺癌的新型抗雌激素药物。ICI46474的早期临床评估。
Br J Cancer. 1971 Jun;25(2):270-5. doi: 10.1038/bjc.1971.33.
4
Structure-activity relationships of anti-oestrogens with regard to interaction with 17-beta-oestradiol in the mouse uterus and vagina.抗雌激素与小鼠子宫和阴道中17-β-雌二醇相互作用的构效关系。
Acta Endocrinol (Copenh). 1971 Mar;66(3):431-47. doi: 10.1530/acta.0.0660431.
5
Mechanism of action of the female sex hormones.女性性激素的作用机制。
Annu Rev Biochem. 1972;41:203-30. doi: 10.1146/annurev.bi.41.070172.001223.
6
The effect of antiestrogens on the nuclear binding of the estrogen receptor.抗雌激素对雌激素受体核结合的影响。
Steroids. 1974 Aug;24(2):209-24. doi: 10.1016/0039-128x(74)90104-4.
7
Estrogen receptor-anti-estrogen complex: atypical binding by uterine nuclei and effects on uterine growth.雌激素受体-抗雌激素复合物：子宫细胞核的非典型结合及其对子宫生长的影响。
Steroids. 1973 Nov;22(5):707-18. doi: 10.1016/0039-128x(73)90118-9.
8
Hormone dependence in breast cancer.乳腺癌中的激素依赖性
Metabolism. 1974 Jan;23(1):75-100. doi: 10.1016/0026-0495(74)90106-1.
9
Formation of estrogen nuclear receptor in uterus: effect of androgens, estrone and nafoxidine.子宫中雌激素核受体的形成：雄激素、雌酮和萘福昔定的作用。
Biochem Biophys Res Commun. 1972 May 26;47(4):662-70. doi: 10.1016/0006-291x(72)90543-8.
Zotero 插件